Cancer
Malignant Prostate Neoplasm
CI-CAN-00005927Explore in graph →
Top-level1,377 active trials24 approved drugs58 evidence items
- NCIt
- C7378
- ICD-10
- C61
- DOID
- 10283
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00005927Explore in graph →
Clinical trials
5,979 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (730)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03436654 | Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma | active not recruiting | Phase 2 | 102 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT04465500 | EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer(Prostate005) | active not recruiting | Phase 2 | 60 | University of VirginiaOTHER | 1 | Apr 27, 2026 |
| clinicaltrials |
| NCT06580015 | [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Apr 27, 2026 | clinicaltrials |
| NCT03682289 | Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | active not recruiting | Phase 2 | 83 | Rahul AggarwalOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT06326216 | Determination of Baseline Levels for Prostate Cancer-Derived Extracellular Vesicles Following Local Treatment of Prostate Cancer | active not recruiting | — | 98 | Mayo ClinicOTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT02960087 | Phase II High Dose Brachytherapy and Low Dose Rate Brachytherapy as Monotherapy in Localized Prostate Cancer | active not recruiting | N/A | 334 | Canadian Cancer Trials GroupNETWORK | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05457257 | Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations | active not recruiting | Phase 4 | 43 | AstraZenecaINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT00951535 | A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17 | active not recruiting | Phase 2 | 251 | Cancer Trials IrelandNETWORK | 1 | Apr 17, 2026 | clinicaltrials |
| NCT03821792 | Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer | active not recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT04215029 | Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans | active not recruiting | N/A | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05047965 | An Investigational Scan (MRI With Dixon Based Sequences) in Detecting Prostate Cancer | active not recruiting | Early Phase 1 | 65 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05055843 | Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer | active not recruiting | N/A | 33 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT07236112 | Study of TRDC002 in the Diagnosis of Patients With PSMA-positive Prostate Cancer | active not recruiting | Phase 1 | 6 | C Ray TherapeuticsINDUSTRY | 1 | Apr 15, 2026 | clinicaltrials |
| NCT05960578 | Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study | active not recruiting | Phase 2 | 8 | University of WashingtonOTHER | 1 | Apr 14, 2026 | clinicaltrials |
| NCT04842890 | Phase II Study of Pencil Beam Scanning Proton Stereotactic Body Radiation Therapy for Prostate Cancer | active not recruiting | Phase 2 | 61 | The New York Proton CenterOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06434649 | Posterior Extra-fascial RARP in Intermediate or High Risk Prostate Cancer | active not recruiting | N/A | 118 | Ning XuOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03361735 | Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Prostate Cancer | active not recruiting | Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Apr 9, 2026 | clinicaltrials |
| NCT00859781 | 177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer | active not recruiting | Phase 2 | 55 | Weill Medical College of Cornell UniversityOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06303713 | LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer | active not recruiting | Phase 1 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 8, 2026 | clinicaltrials |
| NCT06402331 | FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)(AlphaBreak) | active not recruiting | Phase 2 | 110 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 8, 2026 | clinicaltrials |
| NCT00579514 | Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients | active not recruiting | N/A | 21,081 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07214961 | Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)(ARTISAN) | active not recruiting | Phase 1 | 80 | ARTBIO Inc.INDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT04709276 | A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer(CHAMP) | active not recruiting | Phase 2 | 41 | Andrew J. Armstrong, MDOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT04147806 | A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer(PROSINT) | active not recruiting | Phase 1 | 31 | Albert Einstein College of MedicineOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT05219500 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).(TATCIST) | active not recruiting | Phase 2 | 115 | Fusion Pharmaceuticals Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT04300855 | Clinical Trial of Green Tea Catechins in Men on Active Surveillance | active not recruiting | Phase 2 | 115 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT04357925 | Quality of Life in Prostate Cancer Patients(QoLProstateMQ) | active not recruiting | — | 304 | University Hospital Center of MartiniqueOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT03471650 | Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer | active not recruiting | Phase 2 | 150 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 30, 2026 | clinicaltrials |
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | active not recruiting | Phase 1 | 499 | Agenus Inc.INDUSTRY | 2 | Mar 30, 2026 | clinicaltrials |
| NCT04663997 | 177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer | active not recruiting | Phase 2 | 200 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 27, 2026 | clinicaltrials |
| NCT05678322 | Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy | active not recruiting | Phase 3 | 26 | NYU Langone HealthOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT01441687 | Comparing the Reliability of Expressed Prostatic Secretion (EPS) and Post Massage Urine (PMU) for the Prediction of Prostate Cancer Biopsy Outcome | active not recruiting | N/A | 243 | City of Hope Medical CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT02722525 | Cardiac MRI in Measuring the Impact of Anti-androgen Treatment on Cardiac Function in Patients With Prostate Cancer | active not recruiting | N/A | 23 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT03787680 | Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial) | active not recruiting | Phase 2 | 49 | University of Michigan Rogel Cancer CenterOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05096338 | Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer(PCT) | active not recruiting | — | 200 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Mar 23, 2026 | clinicaltrials |
| NCT05658003 | A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer | active not recruiting | Phase 2 | 63 | Novartis PharmaceuticalsINDUSTRY | 1 | Mar 23, 2026 | clinicaltrials |
| NCT06018311 | Hispanic Adapted and Culturally Relevant Exercising Together(HACER) | active not recruiting | N/A | 58 | University of ArizonaOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT06126172 | Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions | active not recruiting | N/A | 125 | Chang Gung Memorial HospitalOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03412396 | Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy | active not recruiting | Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04262609 | Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy | active not recruiting | — | 200 | Consorci Sanitari de TerrassaOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT03663218 | PRE-ProstAtectomy MRI-GuidEd Stereotactic Body RadioTherapy for High-Risk Prostate Cancer Trial (PREPARE SBRT)(PREPARE SBRT) | active not recruiting | N/A | 16 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05343936 | Evaluation of an Active Surveillance Protocol for Prostate Cancer in the Brazilian Population | active not recruiting | — | 490 | Hospital Moinhos de VentoOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06307704 | Lung US for PEEP Optimization in Robotic Radical Prostatectomy or Cystectomy Patients | active not recruiting | N/A | 88 | Nazmy Edward SeifOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT06408597 | Mannitol Versus Nitroglycerin for Kidney Injury Prevention in Robotic-assisted Radical Prostatectomy or Cystectomy | active not recruiting | N/A | 90 | Nazmy Edward SeifOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT05245006 | PET Imaging Study of 89Zr-DFO-YS5 in Men With Prostate Cancer | active not recruiting | Phase 1 | 30 | Robert Flavell, MD, PhDOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT04845503 | Stereotactic MRI-guided Radiation Therapy for Localized prostatE Cancer(SMILE) | active not recruiting | N/A | 68 | University Hospital HeidelbergOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT00578240 | Molecular Studies and Clinical Correlations in Human Prostatic Disease | active not recruiting | — | 5,290 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02905318 | Palbociclib in Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 19 | Canadian Cancer Trials GroupNETWORK | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03561220 | A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer(COMPPARE) | active not recruiting | N/A | 3,000 | University of FloridaOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT03778112 | MRI Guided SBRT for Localized Prostate Cancer | active not recruiting | N/A | 54 | Rush University Medical CenterOTHER | 1 | Mar 9, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 27, 2026source: clinicaltrials